###begin article-title 0
###xml 44 49 <span type="species:ncbi:10090">mouse</span>
Molecular analysis reveals heterogeneity of mouse mammary tumors conditionally mutant for Brca1
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 106 115 106 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 119 127 119 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 424 430 424 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 29 37 <span type="species:ncbi:9606">patients</span>
###xml 440 444 <span type="species:ncbi:10090">mice</span>
Development of therapies for patients with BRCA1 mutations has been hampered by lack of readily available in vitro and in vivo models. We recently showed that transplantation of transgenic mammary tumors as cell suspensions into naive recipients generates reproducible tumors with remarkable stability of gene expression profile. We examined the expression profiles of original and serially transplanted mammary tumors from Brca1 deficient mice, and tumor derived cell lines to validate their use for preclinical testing and studies of tumor biology.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 76 82 76 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
Original tumors, serially transplanted and multiple cell lines derived from Brca1 mammary tumors were characterized by morphology, gene and protein expression, and cell surface markers.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 22 28 22 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 114 119 114 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PyMT </italic>
###xml 124 129 124 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt1 </italic>
###xml 169 175 169 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 554 555 554 555 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 560 566 560 566 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/low </sup>
###xml 109 113 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 601 606 <span type="species:ncbi:9606">human</span>
Gene expression among Brca1 tumors showed more heterogeneity than among previously characterized tumors from MMTV-PyMT and -Wnt1 models. Gene expression data segregated Brca1 tumors into 3 distinct types: basal, mixed luminal, and tumors with epithelial-to-mesenchymal transition (EMT). Serial transplantation of individual tumors and multiple cell lines derived from the original tumors recapitulated the molecular characteristics of each tumor of origin. One tumor had distinct features of EMT and gave rise to cell lines that contained a distinct CD44+/CD24-/low population that may correlate with human breast cancer stem cells.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 132 138 132 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
Although individual tumors expanded by transplantation maintain the genomic profile of the original tumors, the heterogeneity among Brca1 tumors limits the extent of their use for preclinical testing. However, cell lines offer a robust material for understanding tumor biology and response to therapies driven by BRCA1 deficiency.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 184 185 184 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 186 187 186 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 266 272 266 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 275 281 275 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 288 289 288 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 315 321 315 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 407 408 407 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 609 610 609 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 771 772 771 772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 803 809 803 809 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 916 917 916 917 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1129 1130 1129 1130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 55 60 <span type="species:ncbi:9606">women</span>
###xml 108 113 <span type="species:ncbi:9606">Human</span>
###xml 789 797 <span type="species:ncbi:9606">patients</span>
###xml 982 990 <span type="species:ncbi:9606">patients</span>
###xml 1119 1127 <span type="species:ncbi:9606">patients</span>
Breast cancer is the most common neoplastic disease in women and affects approximately 1 out of 10 females. Human breast cancer is a heterogeneous disease with varied clinical course [1,2]. Up to 5% breast cancer cases are attributable to inherited mutations in the BRCA1 or BRCA2 genes [3]. Inherited mutations of BRCA1 (chromosome 17q21) have been linked to increased risk for breast and ovarian cancers [4]. The BRCA1 tumor suppressor plays a major role in DNA damage, signaling, repair and cell cycle control. BRCA1 is also a co-regulator of steroid hormone receptors and modifies steroid hormone action [5]. Carriers of the mutant gene also have significantly higher risk for developing other tumor types, including ovarian, uterine, cervical, and prostate cancers [6]. Breast cancer patients with BRCA1 mutations are more likely to be estrogen receptor (ER) and HER-2 negative, and have mutant or deleted p53 [7]. In spite of advances in detection and clinical management for patients with familiar BRCA1 mutant breast cancer, there has been no significant improvement in therapies and overall survival for these patients [8].
###end p 11
###begin p 12
###xml 160 161 160 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 162 164 162 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 460 462 460 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 597 599 597 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
Microarray analysis has been useful in identifying gene expression signatures that characterize qualities important for biological and clinical classification [9,10]. Phenotypic characterization and microarray profiling of breast tumors reveals distinct subtypes of breast carcinoma that are associated with survival. Five major groups of invasive breast carcinomas have been identified: luminal A, luminal B, HER2 +/ ER -, basal-like, and normal breast-like [10]. The basal-like tumors are typically ER and HER2-negative, have high proliferative rate, and typically show a poor clinical outcome [10].
###end p 12
###begin p 13
###xml 272 274 272 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 405 407 405 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 547 549 547 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 550 552 550 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 708 710 708 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 861 863 861 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 604 609 <span type="species:ncbi:9606">human</span>
###xml 659 664 <span type="species:ncbi:9606">human</span>
BRCA1 and BRCA2 are essential for maintenance of genomic integrity by promoting repair of double-stranded DNA breaks. Following DNA damage, BRCA1 is phosphorylated by the ATM/ATR kinases and recruits multiple factors to the break site that actively participate in repair [11]. BRCA1 associates and co-localizes with RAD51 nuclear foci in mitotic cells along with BRCA2 and BARD1, a BRCA1 binding protein [12]. BRCA1 deficiency leads to impaired double-strand break repair and to enhanced sensitivity to ionizing radiation and genomic instability [11,13]. However, only limited studies are reported using human cells, most of them derived from analysis of one human cell line that is null for BRCA1, HCC1937 [14]. Although BRCA1 replacement increased the resistance to Vinorelbine and Cisplatin, it did not change sensitivity to other agents, such as Docetaxel [14] suggesting that multiple mechanisms may be associated with drug resistance in this cell line.
###end p 13
###begin p 14
###xml 163 172 163 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 176 184 176 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 395 401 395 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 543 545 543 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 618 620 618 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 621 623 621 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 624 626 624 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 708 714 708 714 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 728 730 728 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 731 733 731 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 751 757 751 757 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 925 927 925 927 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 995 999 995 999 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 1055 1060 1055 1060 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1</italic>
###xml 1241 1243 1241 1243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 216 221 <span type="species:ncbi:10090">mouse</span>
###xml 352 357 <span type="species:ncbi:10090">mouse</span>
###xml 594 599 <span type="species:ncbi:10090">mouse</span>
###xml 604 609 <span type="species:ncbi:9606">human</span>
###xml 662 667 <span type="species:ncbi:9606">human</span>
###xml 714 719 <span type="species:ncbi:10090">mouse</span>
###xml 757 762 <span type="species:ncbi:10090">mouse</span>
###xml 968 972 <span type="species:ncbi:10090">mice</span>
###xml 1033 1037 <span type="species:ncbi:10090">mice</span>
###xml 1068 1072 <span type="species:ncbi:10090">mice</span>
Studies of tumor biology and development of novel therapies for tumors associated with BRCA1 deficiency are hampered by the lack of readily available material for in vitro and in vivo studies. Genetically engineered mouse tumors are an excellent tool for studying cancer biology and can potentially improve preclinical studies. Development of multiple mouse models with deletion or mutations in Brca1 targeted to the mammary gland has provided an opportunity to examine the biology and therapeutic implications of BRCA1 loss in breast cancer [15] and some studies find similarities between the mouse and human tumors [11,16,17]. In particular, correlations with human basal-like tumors have been reported in Brca1 mouse models [17,18]. However, using Brca1 mouse mammary models for preclinical development has been limited due to complicated breeding schemes, variable penetrance, and prolonged latency of tumor development [19]. In spite of increased penetrance when mice heterozygous for the Tp53 tumor suppressor are crossed with mice harboring mutant Brca1, these mice develop mammary tumors in over one year, at which time development of lymphomas, which is characteristic of p53-deficient background, also compromises animal survival [20].
###end p 14
###begin p 15
###xml 13 19 13 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 135 140 135 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1</italic>
###xml 215 222 215 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 276 282 276 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 461 466 461 466 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1</italic>
Expansion of Brca1 deficient mammary tumors by transplantation is a useful alternative for generating sufficient material for studying Brca1-associated tumorigenesis. The purpose of our study was to harvest, expand in vivo, and characterize tumors and cell lines derived from Brca1 mammary tumors. The original and transplanted tumors as well as well-characterized cell lines derived from original tumors provide the necessary tools for studying the biology of Brca1-deficient tumors, identification of putative cancer stem cells, and development of novel therapies to improve clinical outcome.
###end p 15
###begin title 16
Materials and methods
###end title 16
###begin title 17
Tumors and serial transplantations of cell suspensions
###end title 17
###begin p 18
###xml 87 141 87 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Guidelines for the Care and Use of Animals in Research</italic>
###xml 172 176 172 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">scid</italic>
###xml 343 353 343 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ad libitum</italic>
###xml 359 364 359 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1</italic>
###xml 364 366 364 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Co</italic>
###xml 367 369 367 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Co</italic>
###xml 374 378 370 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink">exon</italic>
###xml 364 380 364 376 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Co</italic>/<italic>Co</italic>&#916;<italic>exon</italic>11</sup>
###xml 382 385 378 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 385 388 381 384 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 390 399 386 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Cre </italic>
###xml 421 423 417 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 513 515 509 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 189 193 <span type="species:ncbi:10090">mice</span>
###xml 390 394 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 399 404 <span type="species:ncbi:10090">mouse</span>
###xml 982 987 <span type="species:ncbi:10090">mouse</span>
###xml 1007 1011 <span type="species:ncbi:10090">mice</span>
All studies were conducted in an AAALAC accredited facility in compliance with the PHS Guidelines for the Care and Use of Animals in Research. Naive 6-to-8 week old female scid/NCr (BALBc) mice from the NCI Animal Production Program (Frederick, MD) were used as transplant recipients. Autoclaved feed and hyper-chlorinated water were provided ad libitum. The Brca1Co/CoDeltaexon11, p53+/-, MMTV-Cre mouse mammary tumors [21] were dissected and cell suspensions prepared as described by Varticovski and coworkers [22]. In summary, tumors were excised, dissected, mechanically dissociated and forced through a 40 uM mesh. Viable cells were either frozen in freeze down media, or plated at low density in 100 or 150 mm plates in RPMI supplemented with Pen/Strep, glutamine, and 2% FCS for selection of cell lines. Non-adherent cells were removed after 48 hours and surviving clones were isolated using cloning cylinders. For implantation of cell suspensions into naive recipients, the mouse fat pad #4 of SCID mice was visualized through a small skin incision just anterior to the rear leg, and one million cells were injected in 50mu l of RPMI-1640. The incision was closed with a sterile wound clip, which was removed in 7 days.
###end p 18
###begin p 19
###xml 256 258 256 258 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3 </sup>
###xml 259 261 259 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 453 460 453 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 264 268 <span type="species:ncbi:10090">Mice</span>
Tumor size was determined biweekly using caliper measurements (millimeters) in two perpendicular dimensions (length and width). Tumor weights (milligrams) were calculated using the formula for a prolate ellipsoid and assuming a specific gravity of 1.0 g/cm3 [23]. Mice were killed when tumors reached an approximate 1 g of wet weight. Tumors were divided into the following fragments: a portion was used to prepare cell suspensions and further passages in vivo, the remaining was frozen or fixed in 10% neutral-buffered formalin.
###end p 19
###begin title 20
###xml 29 35 29 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
Generation and genotyping of Brca1 tumor cell lines
###end title 20
###begin p 21
###xml 19 25 19 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 73 75 67 69 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
Cells derived from Brca1 mammary tumors were grown at 37degreesC in 5% CO2 in RPMI-1640 media supplemented with increasing concentrations of FBS up to 10%, pen/strep, and glutamine. Over 40 clones were isolated. Sixteen cell lines were developed from 5 original primary tumors and maintained in culture for up to 50 passages in RPMI1640 supplemented with 10%FCS.
###end p 21
###begin p 22
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 120 126 120 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 134 136 134 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 151 157 151 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 163 168 163 168 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Co/Co</sup>
###xml 178 180 178 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 181 183 181 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 208 210 208 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 222 224 222 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 225 227 225 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
Brca1 primary tumors and cell lines were genotyped as described by PCR amplification of sequences specific for the null Brca1 allele [20], conditional Brca1 (Brca1Co/Co) allele [13,21], wild-type p53 allele [20], and CRE [20,24].
###end p 22
###begin title 23
RNA isolation, microarray hybridization and data analysis
###end title 23
###begin p 24
###xml 56 62 56 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 895 897 895 897 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1160 1162 1160 1162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1273 1275 1273 1275 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1485 1487 1485 1487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 387 391 <span type="species:ncbi:10090">mice</span>
###xml 816 821 <span type="species:ncbi:10090">Mouse</span>
Total RNA was isolated from 5 spontaneous (original, 0) Brca1 mammary tumors, 4 tumors from first-passage transplantation into naive recipients (first-passage, 1), 3 tumors from second-passage transplantation into naive recipients (second-passage, 2), and 7 representative original tumor-derived cell lines. Normal virgin mammary glands from three #4 glands of 6-8 wk old C57Bl6 or SCID mice were included in the microarray analysis. Total RNA was isolated using TRIzol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions, followed by DNAse treatment and RNA clean-up (RNeasy Mini Kit, QIAGEN, Valencia, CA). RNA integrity was determined using the RNA 6000 Nano LabChip Kit on Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). RNA was amplified and hybridized overnight to the Agilent Mouse Oligo Microarrays 22 K (G4121AorB) against a common reference total RNA [17]. The co-hybridized samples and reference RNA were washed and scanned on an Axon GenePix 4000B scanner (Molecular Devices, Sunnyvale, CA), analyzed using GenePix 4.1 software, and uploaded to the UNC microarray database where Lowess normalization was performed [25]. Genes were filtered by requiring the Lowess-normalized intensity values in both channels to be > 30. The log2 ratio of Cy5/Cy3 was then reported for each gene. Hierarchical clustering and Gene Set Expression Comparison were performed using BRB Array Tools software developed by the Biometric Research Branch of the NCI [26]. Analysis was restricted to probes that reported values in 75% or more of the samples for comparative analysis or probes that in addition had a minimum 2.5 - fold expression change in either direction from the median value in at least 20% of samples, for hierarchical clustering (defined as most variable genes).
###end p 24
###begin p 25
###xml 128 130 128 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 254 260 254 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 302 307 302 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1</italic>
###xml 307 310 307 310 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 312 315 312 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 315 319 315 319 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 368 373 368 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1</italic>
###xml 373 375 373 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Co</italic>
###xml 376 378 376 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Co</italic>
###xml 373 378 373 378 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Co</italic>/<italic>Co</italic></sup>
###xml 380 383 380 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 383 386 383 386 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 388 397 388 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Cre </italic>
###xml 428 430 428 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 343 347 <span type="species:ncbi:10090">mice</span>
###xml 388 392 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
A comparative analysis of previously published microarray expression data of Brca1-deficient tumors on the same array platform [17] was performed using Gene Cluster 3.0. To this end, we compared gene expression from 22 arrays encompassing the 5 original Brca1 tumors from our study, with 7 tumors from Brca1+/-, p53+/- irradiated (IR, Kohler) mice, and 10 tumors from Brca1Co/Co, p53+/-, MMTV-Cre (Furth) from a previous study [17]. Genes [20,988] were filtered for 80% present (to remove genes that have missing values in greater than 20% of the arrays) and Standard Deviation (SD Gene Vector) >= 1.5 (to remove genes that have standard deviations of observed values less than 1.5, thus selecting for more variable genes across experiments). This filter yielded 339 genes that were used for Hierarchical Clustering. The dendrograms were visualized with Java TreeView.
###end p 25
###begin title 26
Analysis of cell surface markers
###end title 26
###begin p 27
###xml 101 106 <span type="species:ncbi:10090">mouse</span>
###xml 152 157 <span type="species:ncbi:10090">mouse</span>
###xml 201 206 <span type="species:ncbi:10090">mouse</span>
###xml 260 265 <span type="species:ncbi:10090">mouse</span>
###xml 285 288 <span type="species:ncbi:10116">Rat</span>
###xml 635 641 <span type="species:ncbi:9986">rabbit</span>
###xml 650 655 <span type="species:ncbi:10090">mouse</span>
Cells from each cell line were grown to 70% confluence, scraped or trypsinized, stained with PE Anti-mouse CD44 (BD Pharmingen, San Jose, CA), APC Anti-mouse CD24 (Biolegend, San Diego, CA), FITC Anti-mouse CD44 (Southern Biotech, Birmingham, AL), or APC Anti-mouse CD117 (Biolegend). Rat IgG (CHEMICON, Billerica, MA) was used as the isotype control according to manufacturer's instructions. For analysis of Cytokeratins, cells were washed in ice-cold PBS, fixed in 70% ethanol, and stained with either Cytokeratin 5 (Covance, Berkeley, CA) or Cytokeratin 18 (Abcam, Cambridge, MA), and counter-stained with Alexa 488-conjugated anti-rabbit or anti-mouse IgG, respectively. Cells were analyzed by flow cytometry using FACScalibur or LSR II (BD Biosciences, San Jose, CA). Data were collected with Cell Quest Pro software (BD) from no fewer than 10,000 cells and FACSDiVa software (BD) from no fewer than 30,000 cells, respectively.
###end p 27
###begin title 28
Immunohistochemistry
###end title 28
###begin p 29
###xml 275 280 <span type="species:ncbi:10090">mouse</span>
###xml 357 367 <span type="species:ncbi:10141">guinea pig</span>
Paraffin sections of original and transplanted tumors were stained for H&E for histological analysis. Histology of original tumors was compared to transplanted tumors derived from cell suspensions. Immunofluorescent staining was performed for smooth muscle actin (SMA) using mouse A2537 antibody (Sigma, St Louis, MO) at 1:1000 dilution and vimentin, using guinea pig anti-Vimentin antibody (RDI, Concord, MA) at 1:400 dilution. Slides were de-paraffinized and hydrated through a series of xylenes and graded ethanol steps. Heat-mediated epitope retrieval was performed in boiling citrate buffer (pH 6.0) for 15 min. Samples were then cooled to room temperature for 30 min. Secondary antibodies for immunofluorescence were conjugated with Alexa Fluor-488 or -594 fluorophores (1:200, Molecular Probes, Invitrogen, Carlsbad, CA).
###end p 29
###begin p 30
###xml 99 104 <span type="species:ncbi:10090">mouse</span>
###xml 209 215 <span type="species:ncbi:9986">rabbit</span>
###xml 224 229 <span type="species:ncbi:10090">mouse</span>
Cell lines were plated in chamber glass slides, allowed to attach overnight, stained with APC Anti-mouse CD117 (c-kit) from Biolegend, Cytokeratins 5 and 18, and counter stained with Alexa 488-conjugated anti-rabbit or anti-mouse IgG, respectively.
###end p 30
###begin title 31
Immunoblot analysis
###end title 31
###begin p 32
###xml 71 73 71 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
The analysis of protein levels was performed essentially as described [27]. Membranes were blocked at room temperature for 1 h I nTBS/0.05% Tween-20 (TBS-T) containing 5% non-fat dry milk (monoclonal antibodies) or 5% BSA (polyclonal antibodies) and exposed to primary antibodies overnight at 4degreesC in blocking solution. The following commercial antibodies were used: Keratin 5 (Covance); Keratin 18 (Abcam); CD117 (Abgent; San Diego, CA), p53(S15), PDGF Receptor (Anti-CD140a) (Chemicon), Vimentin (BD Pharmingen), and Actin (Ab-1) (Oncogene Research Products, Cambridge, MA). Membranes were washed twice in TBS-T and incubated with species-specific HRP-labeled secondary antibodies in TBS-T for 1 h. Finally, the membranes were washed in TBS-T three times and the proteins were visualized using ECL Western blotting detection reagents (Amersham, Piscataway, NJ).
###end p 32
###begin title 33
Results
###end title 33
###begin title 34
###xml 28 34 28 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
Gene expression analysis of Brca1 mammary tumors
###end title 34
###begin p 35
###xml 71 77 71 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 336 338 336 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 518 520 518 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 539 541 539 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1A</xref>
###xml 657 663 657 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 1048 1050 1048 1050 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">2A</xref>
###xml 1170 1172 1170 1172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">2B</xref>
###xml 1345 1347 1345 1347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">2A</xref>
###xml 406 411 <span type="species:ncbi:10090">mouse</span>
###xml 432 436 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 457 461 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 479 484 <span type="species:ncbi:10090">mouse</span>
The overall similarity of gene expression profiles among five original Brca1 mammary tumors was assessed by pairwise correlations of microarray log-ratios based on 15,781 probes with reported values in at least 75% of samples. The correlation matrix showed Pearson correlation coefficients for pairwise comparisons of 0.66-0.82 (Figure 1A). These correlation coefficients are lower than those obtained for mouse mammary tumors from MMTV-PyMT (0.79-0.94) or MMTV-Wnt1 (0.87-0.95) mouse tumors using a similar analysis [22] (Additional file 1A). In spite of having a similar size at the time of collection (approximately 1 gm of wet weight), heterogeneity of Brca1 mammary tumors was also evident upon pathological examination of morphology, immunohistochemistry, and immunofluorescence analysis of tumor markers. Although all tumors were adenocarcinomas, the original tumor 0_A1 had areas of whorls and clusters of spindle-shaped tumor cells in a myxomatous stroma, features suggestive of epithelial-to-mesenchymal transition (EMT) (Additional file 2A). Consistently, this tumor was also positive for protein expression of a mesenchymal marker, vimentin (Additional file 2B). No evidence of EMT was found in any of the four other original tumors. One of the other tumors was an adenocarcinoma with features of squamous carcinoma (Additional file 2A).
###end p 35
###begin p 36
###xml 20 26 20 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 33 37 33 37 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(A) </bold>
###xml 138 144 138 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 0 246 0 246 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Characterization of <italic>Brca1 </italic>tumors <bold>(A) </bold>Pearson correlation coefficient matrix for pairwise comparisons of log-ratios among five spontaneous <italic>Brca1 </italic>tumors, based on 15,781 probes with reported values in at least 75% of samples (missing-value filter).</bold>
###xml 246 250 246 250 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(B) </bold>
###xml 289 294 289 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1</italic>
###xml 298 303 298 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1</italic>
###xml 303 306 303 306 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 308 311 308 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 311 315 311 315 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 325 330 325 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1</italic>
###xml 330 332 330 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Co</italic>
###xml 333 335 333 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Co</italic>
###xml 330 335 330 335 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Co</italic>/<italic>Co</italic></sup>
###xml 337 340 337 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 340 343 340 343 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 345 354 345 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Cre </italic>
###xml 491 495 491 495 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(C) </bold>
###xml 702 706 702 706 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(D) </bold>
###xml 1014 1015 1014 1015 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 345 349 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
Characterization of Brca1 tumors (A) Pearson correlation coefficient matrix for pairwise comparisons of log-ratios among five spontaneous Brca1 tumors, based on 15,781 probes with reported values in at least 75% of samples (missing-value filter).(B) Unsupervised Hierarchical Cluster of 5 Brca1, 7 Brca1+/-, p53+/- IR and 10 Brca1Co/Co, p53+/-, MMTV-Cre (Furth) mammary tumors based on 339 genes filtered for present values and minimal variability of expression (see Materials and Methods). (C) The dendrogram corresponds to the summarized data for expression of keratins 5, 8,17,18,19 and 23, that were among the 339 genes. The color of each cell represents the relative expression level of each gene.(D) Unsupervised Hierarchical Cluster of original (0), first- (1) and second- (2) passage tumors based on the 416 probes that in addition to passing intensity and missing-value filters had a minimum 2.5-fold expression change in either direction from the median value in at least 20% of samples (Additional file 1).
###end p 36
###begin title 37
###xml 14 20 14 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 93 98 <span type="species:ncbi:10090">mouse</span>
Comparison of Brca1 tumor expression profiles with other previously reported Brca1-deficient mouse mammary models
###end title 37
###begin p 38
###xml 21 23 21 23 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 24 26 24 26 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 236 238 236 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 303 308 303 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1</italic>
###xml 308 311 308 311 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 313 316 313 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 316 320 316 320 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 337 342 337 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1</italic>
###xml 342 345 342 345 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 347 350 347 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 350 354 350 354 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 384 389 384 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1</italic>
###xml 389 391 389 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Co</italic>
###xml 392 394 392 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Co</italic>
###xml 389 394 389 394 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Co</italic>/<italic>Co</italic></sup>
###xml 396 399 396 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 399 402 399 402 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 404 413 404 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Cre </italic>
###xml 476 481 476 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1</italic>
###xml 783 784 783 784 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S3">3</xref>
###xml 834 836 834 836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 849 854 849 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1</italic>
###xml 854 857 854 857 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 859 862 859 862 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 862 866 862 866 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 885 890 885 890 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1</italic>
###xml 1016 1018 1016 1018 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1042 1048 1042 1048 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 1096 1101 1096 1101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1</italic>
###xml 1207 1213 1207 1213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 1250 1255 1250 1255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1</italic>
###xml 1335 1337 1335 1337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1599 1601 1599 1601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1C</xref>
###xml 208 213 <span type="species:ncbi:10090">mouse</span>
###xml 320 324 <span type="species:ncbi:10090">mice</span>
###xml 404 408 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
In previous studies [17,28] Brca1 loss was found to give rise to mammary tumors with a primarily basal-like phenotype. Two models with Brca1 deficiency were featured in a large study that used multiple other mouse mammary tumor models [17], and included 7 mammary tumors that arose after irradiation of Brca1+/-, p53+/- mice (designated Brca1+/-, p53+/- IR-Koller) and 10 tumors from Brca1Co/Co, p53+/-, MMTV-Cre strain, equivalent to the tumors used in our study (designated Brca1-Furth). Since the same array platform and common reference RNA had been used for those studies, we performed an analysis of all 22 samples as described in Methods and found 339 that distinguished these samples. Unsupervised Hierarchical Clustering using these 339 most variable genes (Additional file 3) separated the tumors in 3 main clusters (Figure 1B). All seven Brca1+/-, p53+/- IR-Koller and 3/10 Brca1-Furth tumors showed a basal-type phenotype, previously segregated in Group IV, and characterized by expression of Keratin 5 [17]. Four of the original Brca1 tumors from our study clustered with those four Brca1-Furth tumors that had mixed basal and luminal features. An additional cluster was formed by the original Brca1 tumor A1 from our study and three of Brca1-Furth tumors previously segregated in Group II tumors of spindloid morphology [17]. This cluster showed mesenchymal-like features that included lack of epithelial markers, such as keratins. Moreover, the pattern of expression of keratins across all 339 filtered genes further defined separation of all 22 tumors into the same 3 groups (Figure 1C). Thus, although the majority of Brca1-deficient tumors are basal-like, some have mixed basal and luminal characteristics, and a third group has features consistent with EMT.
###end p 38
###begin title 39
Serial transplantation generates tumors with a stable gene expression profile
###end title 39
###begin p 40
###xml 36 42 36 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 296 302 296 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 455 456 455 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S4">4</xref>
###xml 647 649 647 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1D</xref>
###xml 1056 1057 1056 1057 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S4">4</xref>
###xml 1242 1248 1242 1248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
Given the apparent heterogeneity of Brca1 mammary tumors, we examined the extent to which serial transplantations of individual tumors affect gene expression. Cell suspension from one original (0_A) tumor was transplanted into naive recipients. Unsupervised Hierarchical Clustering of 5 original Brca1 mammary tumors (0), 4 first-passage (1) and 3 second-passage (2) tumors from 0_A tumor were performed based on 416 most variable probes (Additional file 4). This analysis showed that the transplanted tumors segregated into a single branch closer to the tumor of origin, and further subdivided into two groups according to passage number (Figure 1D). As suggested by the Pearson correlation analysis, evidence that all original tumors were heterogeneous was indicated by the long distance of each sample from the immediate tree node above. Gene expression differences between 0_A tumor and the average of gene expression in all transplanted tumors showed 76 upregulated and 79 downregulated genes whose expression changed at least 3-fold (Additional file 4). However, comparison of gene expression between the first and second passage tumors showed no genes with significantly different expression (p = 0.2). Thus, serial transplantation of Brca1 mammary tumors resulted in minimal gene expression profile changes.
###end p 40
###begin p 41
###xml 12 18 12 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 139 141 139 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 539 540 539 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S5">5</xref>
###xml 73 77 <span type="species:ncbi:10090">mice</span>
###xml 210 214 <span type="species:ncbi:10090">mice</span>
###xml 468 472 <span type="species:ncbi:10090">mice</span>
###xml 1043 1047 <span type="species:ncbi:10090">mice</span>
Because the Brca1 original tumors used for our studies were generated in mice bred in a mixed strain background composed mostly of C57Bl6 [21], and cell suspensions were transplanted into immunosuppressed SCID mice, we hypothesized that some of the genetic differences between the original and transplanted tumors could be associated with differences in the genetic background. Thus, we re-analyzed tumor samples with normal virgin mammary glands from C57Bl6 and SCID mice using the 416 most variable probes defined above (Additional file 5). This analysis revealed that several immune response genes, including Histocompatibility 2, class II antigen A, alpha (H2-aA), Histocompatibility 2, class II, locus Mb1 (H2-DMb1) and Histocompatibility 2, class II antigen A, beta 1 (H2-Ab1), as well as Lymphotoxin B (Ltb), and Interleukin 15 (Il15) were downregulated in both, the transplants and normal SCID mammary gland as compared to original tumors and normal C57Bl mammary gland. These data are consistent with immunodeficient genotype of SCID mice, and confirms that many of the differences in gene expression between the original and transplanted tumors are due to differences in genetic background.
###end p 41
###begin p 42
###xml 685 687 685 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
The final analysis between the original and transplanted tumors showed that several of the upregulated genes in the transplanted tumors were associated with growth, metastasis, and cancer stem cells, such as Wnt inhibitory factor 1 (Wif1), Notch gene homolog 4 (Notch4), Hormonally-regulated Neu-associated kinase (Hunk), Sprouty homolog 1 (Spry1), Twist gene homolog 1 (Twist1), and Aldehyde dehydrogenase 3 family, member B1 (Aldh3b1). In addition, apoptosis-associated Phorbol-12-myristate-13-acetate-induced protein 1 (Pmaip1) was among the genes downregulated in transplanted tumors. These data are consistent with the accelerated growth observed in serially transplanted tumors [22].
###end p 42
###begin title 43
Expression profiling of cell lines and comparative analysis with the tumors of origin
###end title 43
###begin p 44
###xml 35 41 35 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 282 287 282 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1</italic>
###xml 287 290 287 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Co </italic>
###xml 287 290 287 290 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Co </italic></sup>
###xml 294 298 294 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 365 370 365 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1</italic>
###xml 370 373 370 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Co </italic>
###xml 370 373 370 373 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Co </italic></sup>
###xml 455 459 455 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 467 469 467 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 488 489 488 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S6">6</xref>
###xml 570 576 570 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 1045 1047 1045 1047 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
The differences between individual Brca1 tumors prompted us to generate and characterize multiple cell lines from each original mammary tumor. To ensure that all 16 cell lines derived from 5 original tumors were free of non-mammary cellular components, we genotyped these cells for Brca1Co and p53 alleles. We confirmed that all cell lines contained the recombined Brca1Co allele and, as shown for primary mammary tumors in this model, lost the wild type p53 allele [20] (Additional file 6). Microarray expression analysis of 7 representative cell lines from 3 original Brca1 tumors were compared to the individual tumors of origin. Cell lines B1.1, B1.2, and B1.15 were generated from the original tumor 0_B1, and the cell line RP3 was derived from 0_RP tumor. Cell lines A1.1, A1.8 and A1.10 were derived from the original tumor 0_A1. This analysis revealed 1,660 most variable genes. Unsupervised Hierarchical Clustering of all 12 samples using these 1,660 genes showed that the cell lines were discriminated from the original tumors (Figure 2A). However, all cell lines derived from the same tumor clustered together in the same sub-branch of the tree, indicating that molecular features of the original tumor are preserved in each set of cell lines derived from that tumor. Some of the differences in gene expression between original tumors and cell lines included downregulation of c-kit (CD117) and further downregulation Cytokeratins 23, 19, 18, 14, 13 and 8, in cell lines. Vimentin, Platelet-Derived Growth Factor receptor alpha (Pdgfr alpha) and beta (Pdgfr beta) were among genes that were upregulated in cell lines consistent with adaptation to tissue culture conditions.
###end p 44
###begin p 45
###xml 20 26 20 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 37 41 37 41 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(A) </bold>
###xml 0 330 0 330 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Characterization of <italic>Brca1 </italic>cell lines <bold>(A) </bold>Unsupervised Hierarchical Cluster of original tumors (0) and cell lines using the 1660 probes that in addition to passing intensity and missing-value filters had a minimum 2.5-fold expression change in either direction from the median value in at least 20% of samples (most variable genes)</bold>
###xml 332 336 332 336 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(B) </bold>
###xml 597 601 597 601 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(C) </bold>
Characterization of Brca1 cell lines (A) Unsupervised Hierarchical Cluster of original tumors (0) and cell lines using the 1660 probes that in addition to passing intensity and missing-value filters had a minimum 2.5-fold expression change in either direction from the median value in at least 20% of samples (most variable genes). (B) Unsupervised Hierarchical Cluster of the original tumors 0_A1 and 0_B1 along with the cell lines derived from them. Cluster was based on the 914 genes reporting at least 4-fold difference in expression ratios between original tumor 0_A1 vs original tumor 0_B1. (C) Cell lines were stained with specific fluorescently-conjugated mAb to Cytokeratin 18, Platelet-derived growth factor receptor (Pdgfr) alpha or beta, as indicated, in parallel with appropriate isotype control-matched mAb and analyzed by flow cytometry. In the histograms shown, the thick black line represents positive staining and the gray filled lines represent the isotype control-matched staining. The percent of positive cells after compensation is shown on the upper right of each panel.
###end p 45
###begin p 46
###xml 650 653 650 653 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-07</sup>
###xml 868 870 868 870 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 1144 1146 1144 1146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1147 1149 1147 1149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
To further assess the conservation of features from original tumors to cell lines, we applied the Gene Set Expression Comparison tool. This tool analyzes pre-defined gene sets for differential expression among pre-defined classes, and indicates which gene set(s) contain more differentially expressed genes than expected by chance. A gene set representing differences in gene expression between the two original tumors 0_A1 and 0_B1 was generated that contained 914 probes either up- or down-regulated by at least 4-fold. This gene set was enriched in genes that were also differentially expressed among the cell lines, with high significance (p < 1e-07). Consistently, Unsupervised Hierarchical Clustering of those original tumors and cell lines based on the 914 differentially expressed probes showed that the cell lines segregated with each tumor of origin (Figure 2B). Genes with differences in expression that were maintained in the original 0_A1 tumor and in cell lines derived from this tumor as compared to 0_B1 tumor and its respective cell lines included loss of CD24a, indicating a possible enrichment in putative cancer stem cells [29,30]. These data indicate that although the original tumors are heterogeneous, the groups of cell lines derived from each one of them are similarly different from each other.
###end p 46
###begin title 47
Correlation of gene expression profile with protein expression
###end title 47
###begin p 48
###xml 240 242 240 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2C</xref>
###xml 278 279 278 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S7">7</xref>
###xml 383 385 379 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2C</xref>
###xml 421 422 417 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S7">7</xref>
###xml 665 666 658 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S7">7</xref>
###xml 941 942 934 935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S8">8</xref>
We examined the expression of several gene products in all cell lines by Flow Cytometry and Western Blot. Although Cytokeratin 18 was downregulated in all cell lines by expression profiling, the protein was still detectable by FACS (Figure 2C) and Western Blot (Additional file 7). Upregulation of Pdgfr alpha which was detected by microarray analysis, was confirmed by FACS (Figure 2C) and Western blot (Additional file 7), while only a low level of Pdgfr beta protein was detected in some cell lines. Variable expression of Vimentin and CD117 (c-kit) and a consistent loss of Cytokeratin 5 in all cell lines was observed by Western blot analysis (Additional file 7) which correlated with gene expression. Interestingly, cell lines derived from anterior and posterior tumors differed in expression of CD117 (c-kit) with protein expression detected only in cell lines derived from tumors arising in posterior mammary glands (Additional file 8).
###end p 48
###begin title 49
###xml 50 56 50 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
Detection of putative cancer stem cell markers in Brca1 cell lines
###end title 49
###begin p 50
###xml 73 74 73 74 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 79 83 79 83 <sup xmlns:xlink="http://www.w3.org/1999/xlink">low </sup>
###xml 181 183 181 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 184 186 184 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 375 381 375 381 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/low </sup>
###xml 529 531 529 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 620 621 620 621 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 626 632 626 632 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/low </sup>
###xml 745 746 745 746 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 751 757 751 757 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/low </sup>
###xml 789 791 789 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 922 924 922 924 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3C</xref>
###xml 993 994 993 994 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 999 1005 999 1005 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/low </sup>
###xml 1206 1212 1206 1212 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/low </sup>
###xml 1419 1425 1419 1425 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/low </sup>
###xml 1683 1685 1683 1685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 35 40 <span type="species:ncbi:9606">human</span>
###xml 168 173 <span type="species:ncbi:10090">mouse</span>
###xml 1067 1072 <span type="species:ncbi:9606">human</span>
###xml 1460 1465 <span type="species:ncbi:10090">mouse</span>
###xml 1589 1593 <span type="species:ncbi:10090">mice</span>
Recent studies identified putative human breast cancer stem cells by CD44+/CD24low cell surface markers that correspond to normal mammary gland-initiating cells in the mouse model [29,30]. Because we found a decrease in CD24a gene expression in the original 0_A1 tumor and in all cell lines derived from this tumor, we examined whether these cells contain a distinct CD44+/24-/low population. We performed flow cytometry on multiple cell lines representative of 0_A1 and all 5 original tumors using CD44 and CD24 markers (Figure 3A). Remarkably, the A1.1 cell line which is derived from 0_A1 tumor showed up to 2.6% CD44+/CD24-/low cells. Analysis of additional cell lines showed that all cell lines derived from 0_A1 tumor were enriched in CD44+/CD24-/low population with 1.32-5% (Figure 3A and data not shown). In contrast, this cell population was less than 1% in all other cell lines derived from other tumors (Figure 3C). Specifically, B1.15 had 0.39%, P2.1 0.60%, and P3.17 0.46% of CD44+/CD24-/low cells. Thus, enrichment in cells with markers consistent with human cancer-initiating cells is preserved in the cell lines derived from the tumor that has features of EMT. In contrast to small CD44+/24-/low population, 50-80% of all cell lines had CD24+ or CD44+/24+ fractions, which makes these markers unlikely to represent a stem cell-enriched population. There have been no previous studies implicating CD44+24-/low population as cancer stem cells in mouse models. Our subsequent studies confirmed stem cell nature of this population by their capacity of reconstituting tumors in mice, drug resistance, and expression of many genes associated with normal stem cell biology [31].
###end p 50
###begin p 51
###xml 48 54 48 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 0 66 0 66 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Characterization of cancer stem cell markers in <italic>Brca1 </italic>cell lines. </bold>
###xml 169 172 169 172 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(A)</bold>
###xml 182 185 182 185 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(B)</bold>
###xml 408 412 408 412 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(C) </bold>
###xml 713 714 713 714 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 719 721 719 721 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
Characterization of cancer stem cell markers in Brca1 cell lines. Cell lines A1.1, B1.15, P2.1 and P3.17 were stained with fluorescently-conjugated mAb specific to CD44 (A), or CD24 (B), in parallel with isotype control-matched mAb and analyzed by flow cytometry. In the histograms shown, the thick black line represents positive staining and the gray filled lines represent the isotype control-matched mAb. (C) Bivariate plots represent the double staining of cell lines with fluorescently-conjugated CD44 and CD24 mAb. The quadrants are gated based on isotype controls and separate the double positive, single positive, and double negative populations. The percent of positive fraction for single label and CD44+/CD24- cells after compensation are indicated in each panel.
###end p 51
###begin title 52
Discussion
###end title 52
###begin p 53
###xml 89 91 89 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 92 94 92 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 95 97 95 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 98 100 98 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 137 142 <span type="species:ncbi:10090">mouse</span>
###xml 523 528 <span type="species:ncbi:9606">human</span>
In spite of previously established genomic instability associated with Brca1 deficiency [16,27,32-34], transplantation of original Brca1 mouse mammary tumors into naive recipients and generation of cell lines from these tumors provides a reliable source of material with relatively stable expression profile. However, due to significant heterogeneity among the original tumors, a panel of individual original tumors will be required for selection of a subset of tumors with appropriate characteristics and correlation with human disease.
###end p 53
###begin p 54
###xml 167 169 167 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 170 172 170 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 582 590 582 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 1052 1054 1052 1054 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 28 33 <span type="species:ncbi:10090">mouse</span>
###xml 131 135 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 423 428 <span type="species:ncbi:10090">mouse</span>
###xml 472 477 <span type="species:ncbi:10090">mouse</span>
###xml 766 771 <span type="species:ncbi:9606">human</span>
###xml 789 794 <span type="species:ncbi:10090">mouse</span>
###xml 899 904 <span type="species:ncbi:10090">mouse</span>
###xml 1037 1042 <span type="species:ncbi:9606">human</span>
###xml 1070 1075 <span type="species:ncbi:9606">human</span>
###xml 1337 1342 <span type="species:ncbi:10090">mouse</span>
Transplantation of multiple mouse mammary tumor models into naive recipients revealed remarkable stability of the cancer genome in MMTV-PyMT and -Wnt1 mammary models [22,35]. Similarly, transplantation of a Brca1 tumor for 2 subsequent passages preserved the molecular features associated with the tumor of origin. However, we found significant differences among the original Brca1 tumors, not previously detected in other mouse mammary models. Thus, in contrast to other mouse mammary tumor models in which the genomic features allow pooling multiple original tumors for expansion in vivo to provide virtually unlimited starting material, Brca1 mammary tumors should be analyzed individually and not pooled. Previous studies found significant discrepancies between human disease and some mouse Brca1 deficient tumor models. These differences are likely to reflect the innate heterogeneity of Brca1 mouse mammary tumors and analysis of multiple individual tumors would be required for selection of appropriate tumors that correlate with human disease [28]. In addition, human BRCA1-associated breast and ovarian cancers are multifocal and frequently arise in the contralateral breast. Future studies need to be performed to determine whether differences in gene expression at multiple sites correlate with the heterogeneity found in the mouse models and whether these differences correspond to mixed responses to therapy.
###end p 54
###begin p 55
###xml 199 201 199 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 400 404 400 404 <sup xmlns:xlink="http://www.w3.org/1999/xlink">low </sup>
###xml 503 505 503 505 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 603 605 603 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 789 791 789 791 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 928 930 928 930 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 1081 1082 1081 1082 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1087 1093 1087 1093 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/low </sup>
###xml 1187 1193 1187 1193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 1215 1217 1215 1217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 1295 1301 1295 1301 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 34 38 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 44 49 <span type="species:ncbi:10090">mouse</span>
We have previously described that MMTV-PyMT mouse mammary tumors arise earlier in anterior mammary gland, have accelerated tumor growth and can be separated from posterior tumors by gene expression [22]. Our current results pose the intriguing possibility that anterior mammary tumors, such as the original 0_A1 tumor, may be enriched in cancer stem cells. Previous studies indicated that normal CD24low mammary cells are myoepithelial and have high mammary fat pad reconstitution capacity, whereas CD24+ population have low capacity for reconstitution and thus are devoid of normal mammary stem cells [30]. In addition, a recent report showed that freshly isolated normal mammary CD24+ cells have the capacity to form mammospheres. However, when these cells are briefly cultured, the CD24- population becomes enriched in mammosphere-forming and mammary-gland repopulating cells, indicative of a switch in stem cell population [36]. In our studies, the cell lines derived from the original 0_A1 mammary tumor, but not cell lines from posterior tumors contained a population of CD44+/CD24-/low cells. We recently confirmed that cells expressing these markers define a cancer stem cell in Brca1 deficient cell lines [31]. Analysis of additional markers that distinguish the anterior and posterior Brca1 tumors, and their capacity for tumor reconstitution need to be performed to test this hypothesis.
###end p 55
###begin p 56
###xml 296 302 296 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 528 530 528 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 836 838 829 831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 932 934 925 927 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 213 218 <span type="species:ncbi:10090">mouse</span>
###xml 911 916 <span type="species:ncbi:9606">human</span>
###xml 1134 1139 <span type="species:ncbi:9606">human</span>
###xml 1144 1149 <span type="species:ncbi:10090">mouse</span>
Although transplantation preserves gene expression profile of the original Brca1 deficient tumor, it offers only a limited potential for tumor expansion for further studies since the starting material is a single mouse tumor. Analysis of multiple cell lines derived from each one of the original Brca1 tumors revealed additional characteristics of these tumors. In spite of changes consistent with exposure to tissue culture conditions and adaptation to growth as monolayer, such as further loss of basal marker, Cytokeratin 5 [37], and gain in expression of Pdgfr alpha and beta, each group of cell lines segregated with their own tumor of origin. Cell lines derived from a tumor with EMT features, 0_A1, lost expression of keratins, and contained a distinct subpopulation of breast cancer stem cells that express CD44+/CD24- markers [31]. Loss of keratin expression has been correlated with poor prognosis in human breast cancer [38]. To our knowledge, the correlation between enrichment in breast cancer stem cells and EMT features has not previously been reported. It would be important to determine whether other BRCA1-deficient human and mouse tumors with EMT features are enriched in putative breast cancer stem cells.
###end p 56
###begin title 57
Conclusion
###end title 57
###begin p 58
###xml 54 56 54 56 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 57 59 57 59 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 60 62 60 62 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 302 308 302 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 609 618 609 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 622 629 622 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
Genetic instability associated with BRCA1 deficiency [28,33,34] is believed to be responsible for therapeutic failures, but the role of breast cancer stem cells in tumor progression and drug resistance in this disease are not known. Heterogeneity of gene expression in tumors originating from the same Brca1 genetic lesion indicates that these tumors may have distinct biology and respond differently to therapies. Serially transplanted tumors and cell lines derived from these tumors recapitulate the gene expression pattern of the tumor of origin and provide potentially useful tool for preclinical studies in vitro and in vivo, and studies of Brca1-associted cancer stem cells.
###end p 58
###begin title 59
Competing interests
###end title 59
###begin p 60
The author(s) declare that they have no competing interests.
###end p 60
###begin title 61
Authors' contributions
###end title 61
###begin p 62
MHW generated cell lines from tumors, characterized them by flow cytometry and western blot, genotyped and isolated RNA from tumors and cell lines, and drafted the manuscript. AIR contributed to the analysis and interpretation of microarray data and helped to draft the manuscript. JIH performed mRNA microarray hybridization, immunohistochemistry and contributed to the analysis and interpretation of microarray data. AIR and JIH contributed equally to the manuscript. MGH performed serial transplantation of tumor suspensions. MRA performed pathological assessment of tumor specimens. CMP supervised microarray analysis, data interpretation and critical review of the manuscript. LV designed the study, participated in data interpretation and manuscript preparation. All authors read and approved the final manuscript.
###end p 62
###begin title 63
Disclaimer
###end title 63
###begin p 64
###xml 115 120 <span type="species:ncbi:9606">Human</span>
The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organization imply endorsement by the U.S. Government.
###end p 64
###begin title 65
Supplementary Material
###end title 65
###begin title 66
Additional file 1
###end title 66
###begin p 67
###xml 48 52 48 52 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(A) </bold>
###xml 275 279 275 279 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(B) </bold>
###xml 22 26 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 163 167 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 390 394 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
Overall similarity of MMTV-driven tumor models. (A) Pearson correlation coefficient matrix for pairwise comparisons of log-intensity values among four spontaneous MMTV-PyMT tumors, based on 18,882 probes with reported values in at least 75% of samples (missing-value filter).(B) Pearson correlation coefficient matrix for pairwise comparisons of log-intensity values among four spontaneous MMTV-wnt1 tumors, based on 21,860 probes with reported values in at least 75% of samples (missing-value filter).
###end p 67
###begin p 68
Click here for file
###end p 68
###begin title 69
Additional file 2
###end title 69
###begin p 70
###xml 17 23 17 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 31 35 31 35 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(A) </bold>
###xml 60 66 60 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 601 605 601 605 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(B) </bold>
Heterogeneity of Brca1 tumors. (A) H&E staining of original Brca1 tumors shows three representative types of morphology. A1 tumor shows features of adenosquamous carcinoma composed of sheets of squamous epithelial cells with eosinophilic cytoplasm and large leptochromatic nuclei. Some cells also form clusters of irregular glands. Several areas have whorls and clusters of spindle-shaped tumor cells suggestive of EMT. RP tumor shows features of, glandular carcinoma with no evidence of EMT. RA tumor has features of squamous nonkeratinizing Carcinoma. This tumor also does not show evidence of EMT. (B) Immunofluorescent detection of vimentin (red) and SMA (green) (right panels) shows mesenchymal features (vimentin) in tumor 0_A1. SMA stains fibroblasts only and not tumor cells, and is used here as control.
###end p 70
###begin p 71
Click here for file
###end p 71
###begin title 72
Additional file 3
###end title 72
###begin p 73
###xml 373 379 373 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 421 426 421 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1</italic>
###xml 426 429 426 429 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 431 434 431 434 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 434 438 434 438 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 487 492 487 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1</italic>
###xml 492 494 492 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Co</italic>
###xml 495 497 495 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Co</italic>
###xml 492 497 492 497 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Co</italic>/<italic>Co</italic></sup>
###xml 499 502 499 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 502 505 502 505 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 507 516 507 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Cre </italic>
###xml 547 549 547 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 34 39 <span type="species:ncbi:10090">mouse</span>
###xml 462 466 <span type="species:ncbi:10090">mice</span>
###xml 507 511 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
List of most variable genes among mouse models with Brca1 deficiency. List of 339 probes that passed intensity and missing-value filters and had Standard Deviation (SD Gene Vector) >= 1.5 (to remove genes that have standard deviations of observed values less than 1.5, thus selecting for more variable genes across experiments), among 22 arrays encompassing the 5 original Brca1 tumors from our study, with 7 tumors from Brca1+/-, p53+/- irradiated (IR, Kohler) mice, and 10 tumors from Brca1Co/Co, p53+/-, MMTV-Cre (Furth) from a previous study [17]. Expression ratios for individual tumors are listed.
###end p 73
###begin p 74
Click here for file
###end p 74
###begin title 75
Additional file 4
###end title 75
###begin p 76
###xml 56 62 56 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 308 314 308 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
List of most variable genes among original and passaged Brca1 mammary tumors. List of 416 probes that in addition to passing intensity and missing-value filters had a minimum 2.5-fold expression change in either direction from the median value in at least 20% of samples, encompassing 5 original independent Brca1 mammary tumors, 4 first-passage and 3 second-passage tumors. Expression ratios for original tumor 0_A1 and the average of expression ratios for transplanted tumors, as well as their fold differences are listed.
###end p 76
###begin p 77
Click here for file
###end p 77
###begin title 78
Additional file 5
###end title 78
###begin p 79
###xml 177 178 177 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S8">8</xref>
###xml 262 266 <span type="species:ncbi:10090">mice</span>
Unsupervised Hierarchical Cluster. Unsupervised Hierarchical Cluster of genes and samples using 416 most variable genes across original and transplanted tumors (Additional file 8). Expression data from normal virgin mammary glands dissected from C57Bl6 and SCID mice were included in the analysis to define the contribution of genetic background to the differential gene expression. In the vertical axis, genes were clustered according to similarities in relative expression ratios. Gene clusters associated with genetic background are detailed on the side.
###end p 79
###begin p 80
Click here for file
###end p 80
###begin title 81
Additional file 6
###end title 81
###begin p 82
###xml 14 20 14 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 142 146 142 146 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(A) </bold>
###xml 154 159 154 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1</italic>
###xml 159 164 159 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">null </italic>
###xml 159 164 159 164 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>null </italic></sup>
###xml 171 175 171 175 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(B) </bold>
###xml 373 378 373 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1</italic>
###xml 378 383 378 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink">null </italic>
###xml 378 383 378 383 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>null </italic></sup>
Genotyping of Brca1 cell lines by PCR. Photographs of ethidium bromide-stained 1% agarose gels showing the products of PCR genotyping for p53 (A) and the Brca1null allele (B) using genomic DNA from the indicated cell lines. L, molecular weight marker. C, p53 positive control. All cell lines used in this study were tested and showed loss of p53 allele and presence of the Brca1null allele.
###end p 82
###begin p 83
Click here for file
###end p 83
###begin title 84
Additional file 7
###end title 84
###begin p 85
###xml 20 26 20 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
Characterization of Brca1 cell lines by Western blot. Analysis of protein expression in whole cell lysates from 16 Brca1 cell lines using antibodies for Cytokeratin 5 (K5), Cytokeratin 18 (K18), c-kit (CD117), Vimentin, and Platelet-derived growth factor receptor alpha (Pdgfralpha).
###end p 85
###begin p 86
Click here for file
###end p 86
###begin title 87
Additional file 8
###end title 87
###begin p 88
###xml 20 26 20 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 218 222 218 222 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(A) </bold>
###xml 231 234 231 234 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(B)</bold>
Characterization of Brca1 cell lines by flow cytometry. Cell lines derived from anterior (A1.1 and A1.8) or posterior (P2.1 and P3.17) tumors were stained with fluorescently-conjugated antibodies against Cytokeratin 5 (A) or CD117 (B), in parallel with isotype control and analyzed by flow cytometry. In the histograms shown, the thick black line represents positive staining and the gray-filled lines represent the isotype control-matched mAb.
###end p 88
###begin p 89
Click here for file
###end p 89
###begin title 90
Acknowledgements
###end title 90
###begin p 91
The authors thank Crystal Salcido for assistance in data analysis, Barbara J. Taylor for assistance with flow cytometry, Karen MacPherson and Dorothea Dudek for bibliographical assistance. This research was supported in part by the Intramural Research Program of the NIH, National Cancer Institute. Additional support was provided by Federal funds from the National Cancer Institute, under Contract No. N01-C0-12400, and by funds for CMP from the NCI Breast SPORE program to UNC-CH (P50-CA58223-09A1) and RO1-CA-101227-01.
###end p 91
###begin article-title 92
Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer
###end article-title 92
###begin article-title 93
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
###end article-title 93
###begin article-title 94
Breast cancer genetics: what we know and what we need
###end article-title 94
###begin article-title 95
Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2
###end article-title 95
###begin article-title 96
Regulation of progesterone receptor signaling by BRCA1 in mammary cancer
###end article-title 96
###begin article-title 97
Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium
###end article-title 97
###begin article-title 98
###xml 30 38 <span type="species:ncbi:9606">patients</span>
Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype
###end article-title 98
###begin article-title 99
Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BBRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases
###end article-title 99
###begin article-title 100
###xml 112 117 <span type="species:ncbi:9606">human</span>
Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors
###end article-title 100
###begin article-title 101
Repeated observation of breast tumor subtypes in independent gene expression data sets
###end article-title 101
###begin article-title 102
The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability
###end article-title 102
###begin article-title 103
Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage
###end article-title 103
###begin article-title 104
###xml 29 35 <span type="species:ncbi:10090">murine</span>
A targeted disruption of the murine Brca1 gene causes gamma-irradiation hypersensitivity and genetic instability
###end article-title 104
###begin article-title 105
###xml 50 55 <span type="species:ncbi:9606">human</span>
Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents
###end article-title 105
###begin article-title 106
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects
###end article-title 106
###begin article-title 107
###xml 18 22 <span type="species:ncbi:10090">mice</span>
###xml 195 200 <span type="species:ncbi:9606">human</span>
Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer
###end article-title 107
###begin article-title 108
###xml 61 67 <span type="species:ncbi:10090">murine</span>
###xml 97 102 <span type="species:ncbi:9606">human</span>
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors
###end article-title 108
###begin article-title 109
###xml 32 36 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 80 85 <span type="species:ncbi:9606">human</span>
Identification of an integrated SV40 T/t-antigen cancer signature in aggressive human breast, prostate, and lung carcinomas with poor prognosis
###end article-title 109
###begin article-title 110
Role of the tumor suppressor gene Brca1 in genetic stability and mammary gland tumor formation
###end article-title 110
###begin article-title 111
Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis
###end article-title 111
###begin article-title 112
Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation
###end article-title 112
###begin article-title 113
###xml 86 91 <span type="species:ncbi:10090">mouse</span>
Accelerated preclinical testing using transplanted tumors from genetically engineered mouse breast cancer models
###end article-title 113
###begin article-title 114
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human tumor xenograft models in NCI drug development
###end article-title 114
###begin article-title 115
###xml 19 23 <span type="species:ncbi:10090">mice</span>
Tumor formation in mice with conditional inactivation of Brca1 in epithelial tissues
###end article-title 115
###begin article-title 116
Role of tumor necrosis factor-alpha and TRAIL in high-dose radiation-induced bystander signaling in lung adenocarcinoma
###end article-title 116
###begin article-title 117
Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer
###end article-title 117
###begin article-title 118
Schedule-dependent synergy between the heat shock protein 90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin and doxorubicin restores apoptosis to p53-mutant lymphoma cell lines
###end article-title 118
###begin article-title 119
###xml 33 37 <span type="species:ncbi:10090">mice</span>
###xml 78 83 <span type="species:ncbi:9606">human</span>
Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer
###end article-title 119
###begin article-title 120
Prospective identification of tumorigenic breast cancer cells
###end article-title 120
###begin article-title 121
###xml 17 22 <span type="species:ncbi:10090">mouse</span>
CD24 staining of mouse mammary gland cells defines luminal epithelial, myoepithelial/basal and non-epithelial cells
###end article-title 121
###begin article-title 122
Brca1 breast tumors contain distinct CD44+/
###end article-title 122
###begin article-title 123
Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations
###end article-title 123
###begin article-title 124
The role of the BRCA1 tumor suppressor in DNA double-strand break repair
###end article-title 124
###begin article-title 125
BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution
###end article-title 125
###begin article-title 126
###xml 34 39 <span type="species:ncbi:10090">mouse</span>
Harnessing genetically engineered mouse models for preclinical testing
###end article-title 126
###begin article-title 127
Enrichment of a population of mammary gland cells that form mammospheres and have in vivo repopulating activity
###end article-title 127
###begin article-title 128
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma
###end article-title 128
###begin article-title 129
###xml 98 103 <span type="species:ncbi:9606">human</span>
Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells
###end article-title 129

